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Table 1
Patient Characteristics
Age (median, range) 71 (70-76)
Male (n, %) 37 (66%)
HCT-CI score (median, range) 1 (0-5)
Disease (n, %)
AML 26 (46%)
MDS 15 (27%)
CLL 5 (9%)
NHL 4 (7%)
ALL 3 (5%)
MPD 2 (4%)
CML 1 (2%)
Donor Type (n, %)
MUD 44 (79%)
MRD 10 (18%)
Mismatched UD 2 (4%)
Conditioning Regimen (n, %)
Busulfan/Fludarabine 53 (93%)
Melphalan/Fludarabine 2 (4%)
Clofarabine/ATG/TLI 1 (2%)
GVHD Prophylaxis (n, %)
CNI þ Siro  MTX 34 (61%)
CNI þ MTX 9 (16%)
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not differ according to allograft source. The three-year
cumulative incidence of Chronic GVHD was 33% (20-47%).
The three-year cumulative incidence of progression was not
signiﬁcantly different for patients with MDS (60%, 95%CI 44-
73%), MPN (88%, 71-95%), or t-MDS (45%, 15-70%). MDS
patients with IPSS-R Very High and High Risk scores all had
progressive disease within the ﬁrst 100 days. In contrast,
patients with Intermediate Risk scores had equivalent
progression-free survival rates with those in the Very Low
and Low risk groups (Hazard Ratio for progression 1.25, 0.36-
4.32). Patients with donor CD15>90% at day 28 (40% of
patients) deﬁned a group with a low likelihood of disease
progression (Odds Ratio 0.20, p¼.01).
Discussion: For patients with MDS and MPN, TLI/ATG
conditioning was associated with low rates of acute GVHD
and NRM. Patients whose IPSS-R scores at the time of HCT
were Intermediate, Low, and Very Low had signiﬁcantly
lower risks of disease progression than those with High or
Very High risk scores, suggesting early transplantation with
TLI/ATG may result in better long-term outcomes.CNI þ ATG þ MTX 7 (13%)
CNI þ MMF 3 (5%)
Other 3 (5%)10
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Allogeneic hematopoietic stem cell transplantation
(HSCT) can achieve durable remissions in a number of
advanced hematologic malignancies. The advent of reduced
intensity conditioning (RIC) regimens has allowed HSCT to be
offered to increasingly older adults. However, little is known
about the safety of HSCT in patients over the age of 70 years.
The purpose of this retrospective study was to describe the
overall outcomes of patients older than age 70 who under-
went HSCT for hematologic malignancies. We identiﬁed 56
consecutive patients age 70 or older who underwent HSCT at
Massachusetts General Hospital or the Dana-Farber Cancer
Institute between January 2007 and July 2012. Patients were
included in this study if age 70 or older on the day of trans-
plantation. All patients met standard institutional criteria for
HSCT eligibility. The majority of patients underwent trans-
plant for acute leukemia or myelodysplastic syndrome (AML
26,MDS15, CLL5,NHL4,ALL3,MPD2,CML1).Median follow-
up for survivors was 15months (range 2-86). Themedian age
at transplantwas71years (range70-76) and66% (37/56)were
male; themedian HCT-CI scorewas 1 (range 0-5). All patients
received RIC regimens with 93% receiving a busulfan / ﬂu-
darabine regimen. All patients receivedperipheral blood stem
cell grafts; 44 froman8/8matchedunrelateddonor (MUD),10
from a matched related donor (MRD), and 2 from a 7/8
matched unrelated donor. 95% of patients received calci-
neurin inhibitor-based GVHD prophylaxis regimens, most in
combination with sirolimus or methotrexate (Table 1). Of
these 56 patients, 2 died prior to engraftment, one from graft
failure and one from disease progression. Of the 46 patientswho experienced a nadir, the median time to neutrophil
engraftment was 13 days (range 2-31). Maximum cumulative
grade II-IV acute GVHD incidence was 13% and grade III-IV
acute GVHD7%. One year cumulative chronicGVHD incidence
was 37%. One-year progression-free survival was 42% and
one-year overall survival was 55%. The cumulative incidence
of relapsewas 34% and non-relapsemortality was 3.6% at day
100 and 5.5% at 1-year after HSCT. HSCT is a safe and effective
option for patients over the age of 70. Further follow-up and
analysis are needed to determine which patients will derive
beneﬁt from allogeneic transplantation; however, for care-
fully selectedelderlypatients, ageover70shouldnotpreclude
consideration of HSCT.11
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Comparisons of myeloablative conditioning versus
reduced intensity conditioning (RIC) demonstrate a tradeoff
between relapse and more toxicity. Dose intensity across RIC
